Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8N766

UPID:
EMC1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8N766; A8K6F3; Q14700; Q5TG62; Q63HL0; Q63HL3; Q8NBH8

BACKGROUND:
ER membrane protein complex subunit 1 is integral to the endoplasmic reticulum's function, facilitating the energy-independent insertion of membrane proteins. It preferentially accommodates proteins with specific features, playing a pivotal role in the topology of multi-pass membrane proteins like G protein-coupled receptors.

THERAPEUTIC SIGNIFICANCE:
Linked to a severe neurodegenerative disorder, the study of ER membrane protein complex subunit 1 offers a promising avenue for developing targeted treatments. Understanding its role could lead to breakthroughs in therapy for diseases involving membrane protein dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.